Dr Reddys Laboratories (RDY) EBT Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly EBT Margin of 27.78% for Q2 2023, little changed quarter-over-quarter from 27.74% in Q1 2023.

Dr Reddys Laboratories (RDY) EBT Margin (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' EBT Margin history runs 15 years deep, the most recent figure standing at 27.78% for Q2 2023.

In Q2 2023, EBT Margin changed N/A year-over-year to 27.78%; the TTM figure through Jun 2023 stood at 0.0% (changed N/A YoY), while the FY2026 annual figure was 16.31%, down 730.0% from the prior year.
EBT Margin for Q2 2023 stood at 27.78%, roughly flat from 27.74% in the prior quarter.
The five-year high for EBT Margin was 27.78% in Q2 2023, with the low at 10.67% in Q3 2020.
The 5-year median for EBT Margin is 19.97% (2020), against an average of 17.43%.
The sharpest annual moves came in 2019 and 2020: EBT Margin surged 861 bps in 2019, then sank 2386 bps in 2020.
Dr Reddys Laboratories' EBT Margin stood at 13.19% in 2019, then tumbled by 181 bps to 10.67% in 2020, then soared by 306 bps to 22.01% in 2021, then slipped by 4 bps to 21.12% in 2022, then jumped by 32 bps to 27.78% in 2023.
Business Quant data shows RDY's EBT Margin at 27.78% in Q2 2023, 27.74% in Q1 2023, and 21.12% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-10.99%
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	47.58%
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	-0.38%

Download Data